{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:55:38Z","timestamp":1785606938800,"version":"3.56.0"},"reference-count":104,"publisher":"Portland Press Ltd.","issue":"10","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID-19 induces a proinflammatory environment that is stronger in patients requiring intensive care. The cytokine components of this environment may determine efficacy or otherwise of glucocorticoid therapy. The immunity modulators, the aryl hydrocarbon receptor (AhR) and the nuclear NAD+-consuming enzyme poly (ADP-ribose) polymerase 1 (PARP 1) may play a critical role in COVID-19 pathophysiology. The AhR is overexpressed in coronaviruses, including COVID-19 and, as it regulates PARP gene expression, the latter is likely to be activated in COVID-19. PARP 1 activation leads to cell death mainly by depletion of NAD+ and adenosine triphosphate (ATP), especially when availability of these energy mediators is compromised. PARP expression is enhanced in other lung conditions: the pneumovirus respiratory syncytial virus (RSV) and chronic obstructive pulmonary disease (COPD). I propose that PARP 1 activation is the terminal point in a sequence of events culminating in patient mortality and should be the focus of COVID-19 immunotherapy. Potent PARP 1 inhibitors are undergoing trials in cancer, but a readily available inhibitor, nicotinamide (NAM), which possesses a highly desirable biochemical and activity profile, merits exploration. It conserves NAD+ and prevents ATP depletion by PARP 1 and Sirtuin 1 (silent mating type information regulation 2 homologue 1) inhibition, enhances NAD+ synthesis, and hence that of NADP+ which is a stronger PARP inhibitor, reverses lung injury caused by ischaemia\/reperfusion, inhibits proinflammatory cytokines and is effective against HIV infection. These properties qualify NAM for therapeutic use initially in conjunction with standard clinical care or combined with other agents, and subsequently as an adjunct to stronger PARP 1 inhibitors or other drugs.<\/jats:p>","DOI":"10.1042\/bsr20202856","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T08:22:08Z","timestamp":1602836528000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide"],"prefix":"10.1042","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-2804","authenticated-orcid":false,"given":"Abdulla\u00a0A.-B.","family":"Badawy","sequence":"first","affiliation":[{"name":"Formerly School of Health Sciences, Cardiff Metropolitan University, Cardiff, Wales, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"2020103010205418300_B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2020103010205418300_B2","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1111\/bph.15137","article-title":"Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multipronged therapy for ARDS?","volume":"177","author":"Curtin","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"2020103010205418300_B3","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.11.986836","article-title":"A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19","author":"Ge","year":"2020","journal-title":"bioRxiv"},{"key":"2020103010205418300_B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.25259\/IJMS_25_2020","article-title":"Role of PARP-1 inhibition by nicotinamide to modulate host immune response and prevention of cytokine storm in COVID-19","volume":"72","author":"Gharote","year":"2020","journal-title":"Indian J. Med. Sci."},{"key":"2020103010205418300_B5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/nsr\/nwaa037","article-title":"Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury","volume":"7","author":"Liu","year":"2020","journal-title":"Nat. Sci. Rev."},{"key":"2020103010205418300_B6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"2020103010205418300_B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"2020103010205418300_B8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1465-9921-6-42","article-title":"Persistence of lung inflammation and lung cytokines with high resolution CT abnormalities during recovery from SARS","volume":"6","author":"Wang","year":"2005","journal-title":"BMC Respir. Res."},{"key":"2020103010205418300_B9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1164\/rccm.200407-857OC","article-title":"Characterization of cytokine\/chemokine profiles of severe acute respiratory syndrome","volume":"171","author":"Jiang","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2020103010205418300_B10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/infdis\/jit504","article-title":"Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenes","volume":"209","author":"Zhou","year":"2014","journal-title":"J. Infect. Dis."},{"key":"2020103010205418300_B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine"},{"key":"2020103010205418300_B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"2020103010205418300_B13","first-page":"13","article-title":"Lung cytokines and systemic inflammation in patients with COPD","volume":"1","author":"Gearhart","year":"2017","journal-title":"Univ. Louisville J. Resp. Infect."},{"key":"2020103010205418300_B14","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-25639\/v1","article-title":"A potential role for AHR in SARS-CoV-2 pathology","author":"Giovannoni","year":"2020","journal-title":"Res. Sq."},{"key":"2020103010205418300_B15","doi-asserted-by":"crossref","first-page":"e01743","DOI":"10.1128\/JVI.01743-19","article-title":"Murine coronavirus infection activates the aryl hydrocarbon receptor in an indoleamine 2,3-dioxygenase-independent manner, contributing to cytokine modulation and proviral TCDD-inducible-PARP expression","volume":"94","author":"Grunewald","year":"2020","journal-title":"J. Virol."},{"key":"2020103010205418300_B16","doi-asserted-by":"publisher","first-page":"e0163709","DOI":"10.1371\/journal.pone.0163709","article-title":"Respiratory syncytial virus-infected mesenchymal stem cells regulate immunity via interferon Beta and indoleamine-2,3-dioxygenase","volume":"11","author":"Cheung","year":"2016","journal-title":"PLoS ONE"},{"key":"2020103010205418300_B17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0891-5849(03)00237-5","article-title":"Systemic poly (ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients","volume":"35","author":"Hageman","year":"2003","journal-title":"Free Radic. Biol. Med."},{"key":"2020103010205418300_B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1471-2164-7-80","article-title":"In vivo-in vitro toxicogenomic comparison of TCDD-elicited gene expression in Hepa1c1c7 mouse hepatoma cells and C57BL\/6 hepatic tissue","volume":"7","author":"Dere","year":"2006","journal-title":"BMC Genomics"},{"key":"2020103010205418300_B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2567.2009.03054.x","article-title":"The aryl hydrocarbon receptor: a perspective on potential roles in the immune system","volume":"127","author":"Stevens","year":"2009","journal-title":"Immunology"},{"key":"2020103010205418300_B20","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fimmu.2014.00458","article-title":"The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both","volume":"5","author":"Julliard","year":"2014","journal-title":"Front. Immunol."},{"key":"2020103010205418300_B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"2020103010205418300_B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol. Sci."},{"key":"2020103010205418300_B23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4137\/IJTR.S38189","article-title":"Assessment of the human kynurenine pathway: comparisons and clinical implications of ethnic and gender differences in plasma tryptophan, kynurenine metabolites, and enzyme expressions at baseline and after acute tryptophan loading and depletion","volume":"9","author":"Badawy","year":"2016","journal-title":"Int. J. Tryptophan Res."},{"key":"2020103010205418300_B24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bbrc.2008.07.156","article-title":"Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase","volume":"375","author":"Vogel","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2020103010205418300_B25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.18632\/oncotarget.1637","article-title":"Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR","volume":"5","author":"Litzenburger","year":"2014","journal-title":"Oncotarget"},{"key":"2020103010205418300_B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and Functional aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int. J. Tryptophan Res."},{"key":"2020103010205418300_B27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.32527\/2019\/101415","article-title":"Tryptophan metabolism: a versatile area providing multiple targets for pharmacological intervention","volume":"9","author":"Badawy","year":"2019","journal-title":"Egypt. J. Basic Clin. Pharmacol."},{"key":"2020103010205418300_B28","doi-asserted-by":"publisher","first-page":"110770","DOI":"10.1016\/j.exger.2019.110770","article-title":"Kynurenine pathway and human systems","volume":"129","author":"Badawy","year":"2020","journal-title":"Exp. Gerontol."},{"key":"2020103010205418300_B29","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1167\/iovs.02-1106","article-title":"The critical role of IFN-\u03b3 in experimental coronavirus retinopathy","volume":"44","author":"Hooks","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2020103010205418300_B30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1469-7793.2001.00207.x","article-title":"Tryptophan degradation by human placental indoleamine 2,3- dioxygenase regulates lymphocyte proliferation","volume":"535","author":"Kudo","year":"2001","journal-title":"J. Physiol."},{"key":"2020103010205418300_B31","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.4049\/jimmunol.169.4.1810","article-title":"Fc\u03b5RI induces the tryptophan degradation pathway involved in regulating T cell responses","volume":"169","author":"von Bubnoff","year":"2002","journal-title":"J. Immunol."},{"key":"2020103010205418300_B32","doi-asserted-by":"publisher","first-page":"13978","DOI":"10.1073\/pnas.96.24.13978","article-title":"Poly (ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion","volume":"96","author":"Ha","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2020103010205418300_B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"2020103010205418300_B34","doi-asserted-by":"publisher","first-page":"100950","DOI":"10.1016\/j.molmet.2020.01.014","article-title":"The taming of PARP1 and its impact on NAD+ metabolism","volume":"38","author":"Hurtado-Bag\u00e8s","year":"2020","journal-title":"Mol. Metab."},{"key":"2020103010205418300_B35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Molec. Aspects Med."},{"key":"2020103010205418300_B36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/02770900902777791","article-title":"The Ala allele at Val762Ala polymorphism in poly (ADP-ribose) polymerase-1 (PARP1) gene is associated with a decreased risk of asthma in a Turkish population","volume":"46","author":"Tezcan","year":"2009","journal-title":"J. Asthma"},{"key":"2020103010205418300_B37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bcp.2018.01.027","article-title":"PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice","volume":"150","author":"Dharwal","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"2020103010205418300_B38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fimmu.2019.00452","article-title":"Contribution of cytokines to tissue damage during human respiratory syncytial virus infection","volume":"10","author":"Bohmwald","year":"2019","journal-title":"Front. Immunol."},{"key":"2020103010205418300_B39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1677\/joe.0.1810207","article-title":"Role of the hypothalamic\u2013pituitary\u2013adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products","volume":"181","author":"Webster","year":"2004","journal-title":"J. Endocrinol."},{"key":"2020103010205418300_B40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12020-020-02325-1","article-title":"COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications","volume":"68","author":"Pal","year":"2020","journal-title":"Endocrine"},{"key":"2020103010205418300_B41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.mehy.2008.03.019","article-title":"What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients?","volume":"71","author":"Panesar","year":"2008","journal-title":"Med. Hypotheses"},{"key":"2020103010205418300_B42","doi-asserted-by":"publisher","first-page":"e2373","DOI":"10.1371\/journal.pntd.0002373","article-title":"Serum metabolome and lipidome changes in adult patients with primary dengue infection","volume":"7","author":"Cui","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2020103010205418300_B43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2334-5-47","article-title":"High frequency of Fredrickson\u2019s phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus","volume":"5","author":"Albuquerque","year":"2005","journal-title":"BMC Infect. Dis."},{"key":"2020103010205418300_B44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fcimb.2019.00410","article-title":"Serum lipidomics analysis of classical swine fever virus infection in piglets and emerging role of free fatty acids in virus replication in vitro","volume":"9","author":"Ma","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2020103010205418300_B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.imlet.2019.11.004","article-title":"The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO)","volume":"217","author":"Duhalde Vega","year":"2020","journal-title":"Immunol. Lett."},{"key":"2020103010205418300_B46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.imlet.2020.05.007","article-title":"Liver tryptophan 2,3-dioxygenase in the mouse hepatitis virus (MHV-A59) model","volume":"225","author":"Badawy","year":"2020","journal-title":"Immunol. Lett."},{"key":"2020103010205418300_B47","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID-19: what\u2019s next?","volume":"177","author":"Scavone","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"2020103010205418300_B48","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1056\/NEJMc2022236","article-title":"Remdesivir for the treatment of Covid-19 - preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"2020103010205418300_B49","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2020103010205418300_B50","doi-asserted-by":"publisher","first-page":"754","DOI":"10.7326\/M20-1334","article-title":"Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know","volume":"172","author":"Yazdani","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"2020103010205418300_B51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"2020103010205418300_B52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"2020103010205418300_B53","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1038\/srep07176","article-title":"Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon","volume":"4","author":"Thomas","year":"2014","journal-title":"Sci. Rep."},{"key":"2020103010205418300_B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.907","article-title":"Long-term impact of inhaled corticosteroid use in asthma and chronic obstructive pulmonary disease (COPD): review of mechanisms that underlie risks","author":"Singanayagam","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"2020103010205418300_B55","first-page":"1","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"The Recovery Collaborative Group","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"2020103010205418300_B56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2344\/0003-3006-60.1.25","article-title":"Basic and clinical pharmacology of glucocorticosteroids","volume":"60","author":"Becker","year":"2013","journal-title":"Anesth. Progr."},{"key":"2020103010205418300_B57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1042\/bj1500511","article-title":"The regulation of rat liver tryptophan pyrrolase by its cofactor haem \u2013 experiments with haematin and 5-aminolaevulinate and comparison with the substrate and hormonal mechanisms","volume":"150","author":"Badawy","year":"1975","journal-title":"Biochem. J."},{"key":"2020103010205418300_B58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0006-3223(89)90184-4","article-title":"Effects of a suppression test dose of dexamethasone on tryptophan metabolism and disposition in the rat","volume":"25","author":"Morgan","year":"1989","journal-title":"Biol. Psychiat."},{"key":"2020103010205418300_B59","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.1073\/pnas.78.12.7327","article-title":"Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis","volume":"78","author":"Sayama","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2020103010205418300_B60","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0006-291X(87)91431-8","article-title":"The actions of interferons and antiinflammatory agents on induction of indoleamine 2,3-dioxygenase in human peripheral blood monocytes","volume":"144","author":"Ozaki","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2020103010205418300_B61","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1128\/JVI.78.5.2632-2636.2004","article-title":"Role of indoleamine-2,3-dioxygenase in alpha\/beta and gamma interferon- Mediated antiviral effects against herpes simplex virus infections","volume":"78","author":"Adams","year":"2004","journal-title":"J. Virol."},{"key":"2020103010205418300_B62","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/sj.mp.4000995","article-title":"Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy","volume":"7","author":"Capuron","year":"2002","journal-title":"Mol. Psychiat."},{"key":"2020103010205418300_B63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.phrs.2010.10.009","article-title":"Effects pf PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C","volume":"63","author":"Comai","year":"2011","journal-title":"Pharmacol. Res."},{"key":"2020103010205418300_B64","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2020103010205418300_B65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI117009","article-title":"Interferon-\u03b3 induces the synthesis and activation of cytosolic phospholipase A2","volume":"93","author":"Wu","year":"1994","journal-title":"J. Clin. Invest."},{"key":"2020103010205418300_B66","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/j.1460-2075.1996.tb00501.x","article-title":"Interferon-a-induced phosphorylation and activation of cytosolic phospholipase A2 is required for the formation of interferon- stimulated gene factor three","volume":"15","author":"Flati","year":"1996","journal-title":"EMBO J."},{"key":"2020103010205418300_B67","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1073\/pnas.89.9.3917","article-title":"Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme","volume":"89","author":"Masferrer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2020103010205418300_B68","doi-asserted-by":"publisher","first-page":"15280","DOI":"10.1073\/pnas.96.26.15280","article-title":"Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids","volume":"96","author":"Zhang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2020103010205418300_B69","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1476-5381.1989.tb12676.x","article-title":"Glucocorticoids inhibit Prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase\/PGE isomerase","volume":"98","author":"Goppelt-Struebe","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"2020103010205418300_B70","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/ajt.15869","article-title":"Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression","volume":"20","author":"Zhu","year":"2020","journal-title":"Am. J. Transplant."},{"key":"2020103010205418300_B71","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9038","article-title":"Pulse therapy with corticosteroids and intravenous immunoglobulin in the management of severe tocilizumab-resistant COVID-19. A report of three clinical cases","volume":"12","author":"Sheianov","year":"2020","journal-title":"Cureus"},{"key":"2020103010205418300_B72","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial","author":"Jeronimo","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2020103010205418300_B73","article-title":"Hydrocortisone for COVID-19 and severe hypoxia-NCT0434830","author":"Clinical Trials","year":"2020"},{"key":"2020103010205418300_B74","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID- 19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"2020103010205418300_B75","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"2020103010205418300_B76","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/0004563220928361","article-title":"Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin converting enzyme 2 (ACE2)","volume":"57","author":"Zemlin","year":"2020","journal-title":"Ann. Clin. Biochem."},{"key":"2020103010205418300_B77","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"2020103010205418300_B78","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1365-2249.2003.02031.x","article-title":"Nicotinamide is a potent inhibitor of proinflammatory cytokines","volume":"131","author":"Ungerstedt","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"2020103010205418300_B79","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3892\/or.2014.3661","article-title":"Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin","volume":"33","author":"Dom\u00ednguez-G\u00f3mez","year":"2014","journal-title":"Oncol. Rep."},{"key":"2020103010205418300_B80","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1183\/09031936.00025107","article-title":"Nicotinamide abrogates acute lung injury caused by ischaemia\/reperfusion","volume":"30","author":"Su","year":"2007","journal-title":"Eur. Respir. J."},{"key":"2020103010205418300_B81","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1086\/367544","article-title":"Nicotinamide: an oral antimicrobial agent with activity against both mycobacterium tuberculosis and human immunodeficiency virus","volume":"36","author":"Murray","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"2020103010205418300_B82","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-019-08530-5","article-title":"NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression","volume":"10","author":"Bian","year":"2019","journal-title":"Nat. Commun."},{"key":"2020103010205418300_B83","doi-asserted-by":"publisher","first-page":"45099","DOI":"10.1074\/jbc.M205670200","article-title":"Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1","volume":"277","author":"Bitterman","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2020103010205418300_B84","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.18632\/oncotarget.13749","article-title":"Novel PARP1\/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"2020103010205418300_B85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1042\/bj1560381","article-title":"The regulation of rat liver tryptophan pyrrolase activity by reduced nicotinamide-adenine dinucleotide (phosphate): experiments with glucose and nicotinamide","volume":"156","author":"Badawy","year":"1976","journal-title":"Biochem. J."},{"key":"2020103010205418300_B86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1042\/bj1840165","article-title":"Prevention by pyrazole of the effects of chronic ethanol administration on the redox states of the hepatic nicotinamide- adenine dinucleotide (phosphate) couples and on liver and brain tryptophan metabolism in the rat","volume":"184","author":"Punjani","year":"1979","journal-title":"Biochem. J."},{"key":"2020103010205418300_B87","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: a review","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia"},{"key":"2020103010205418300_B88","doi-asserted-by":"publisher","first-page":"e0123460","DOI":"10.1371\/journal","article-title":"Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration","volume":"10","author":"Jones","year":"2015","journal-title":"PLoS ONE"},{"key":"2020103010205418300_B89","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1042\/CS20160153","article-title":"The end of the road for the tryptophan depletion concept in pregnancy and infection","volume":"130","author":"Badawy","year":"2016","journal-title":"Clin. Sci."},{"key":"2020103010205418300_B90","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/molecules25153323","article-title":"Minireview: Exploring the biological cycle of vitamin B3 and its influence on oxidative stress: further molecular and clinical aspects","volume":"25","author":"Doroftei","year":"2020","journal-title":"Molecules"},{"key":"2020103010205418300_B91","doi-asserted-by":"publisher","first-page":"10219","DOI":"10.1038\/s41598-019-46678-8","article-title":"Nicotinamide augments the anti-inflammatory properties of resveratrol through PARP1 activation","volume":"9","author":"Yanez","year":"2019","journal-title":"Sci. Rep."},{"key":"2020103010205418300_B92","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12017-009-8058-1","article-title":"Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons","volume":"11","author":"Liu","year":"2009","journal-title":"Neuromol. Med."},{"key":"2020103010205418300_B93","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.abb.2010.09.016","article-title":"Identifcation of PARP-1 as one of the transcription factors binding to the repressor element in the promoter region of COX-2","volume":"505","author":"Lin","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"2020103010205418300_B94","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12017-018-8483-0","article-title":"Resveratrol improves neuroimmune dysregulation through the inhibition of neuronal toll-like receptors and COX-2 signaling in BTBR T+ Itpr3(tf)\/J Mice","volume":"20","author":"Ahmad","year":"2018","journal-title":"Neuromol. Med."},{"key":"2020103010205418300_B95","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41590-018-0255-3","article-title":"Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation","volume":"20","author":"Minhas","year":"2019","journal-title":"Nat. Immunol."},{"key":"2020103010205418300_B96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fimmu.2020.00031","article-title":"Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD+ synthesis during inflammation and infection","volume":"11","author":"Moffett","year":"2020","journal-title":"Front. Immunol."},{"key":"2020103010205418300_B97","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0021-9258(18)56203-7","article-title":"Relation of tryptophan and niacin to pyridine nucleotides of tissues","volume":"187","author":"Williams","year":"1950","journal-title":"J. Biol. Chem."},{"key":"2020103010205418300_B98","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1079\/BJN19820094","article-title":"Probable mechanisms of regulation of the utilization of dietary tryptophan, nicotinamide and nicotinic acid as precursors of nicotinamide nucleotides in the rat","volume":"48","author":"Bender","year":"1982","journal-title":"Br. J. Nutr."},{"key":"2020103010205418300_B99","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1079\/BJN19860138","article-title":"The metabolism of high intakes of tryptophan, nicotinamide and nicotinic acid in the rat","volume":"56","author":"McCreanor","year":"1986","journal-title":"Br. J. Nutr."},{"key":"2020103010205418300_B100","doi-asserted-by":"publisher","first-page":"12948","DOI":"10.1038\/ncomms12948","article-title":"Nicotinamide riboside is uniquely and orally bioavailable in mice and humans","volume":"7","author":"Trammell","year":"2016","journal-title":"Nat. Commun."},{"key":"2020103010205418300_B101","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.celrep.2019.07.043","article-title":"Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces tanscriptomic and anti-inflammatory signatures","volume":"28","author":"Elhassan","year":"2019","journal-title":"Cell Rep."},{"key":"2020103010205418300_B102","doi-asserted-by":"publisher","first-page":"192e202","DOI":"10.1016\/j.molmet.2019.09.013","article-title":"A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor","volume":"30","author":"Giroud-Gerbetant","year":"2019","journal-title":"Mol. Metab."},{"key":"2020103010205418300_B103","article-title":"Repurposed antiviral drugs for COVID-19 \u2013 interim WHO SOLIDARITY trial results preprint","author":"WHO Solidarity trial consortium","year":"2020","journal-title":"medRxiv"},{"key":"2020103010205418300_B104","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","article-title":"IL4I1 is a metabolic immune checkpoint that activates the AhR and promotes tumor progression","volume":"182","author":"Sadek","year":"2020","journal-title":"Cell"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20202856\/896412\/bsr-2020-2856.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20202856\/896412\/bsr-2020-2856.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T16:01:51Z","timestamp":1669219311000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/doi\/10.1042\/BSR20202856\/226684\/Immunotherapy-of-COVID19-with-poly-ADPribose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":104,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20202856","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,10]]},"article-number":"BSR20202856"}}